---
title: "Coagulation Disorders"
order: 2
category: "Hematology"
---

# Coagulation Disorders

## Overview

Coagulation disorders encompass a spectrum of inherited and acquired conditions characterized by abnormal hemostasis, resulting in either excessive bleeding (hemorrhagic disorders) or inappropriate clotting (thrombotic disorders). Understanding the coagulation cascade, platelet function, and the balance between procoagulant and anticoagulant forces is essential for diagnosing and managing these complex disorders.

### Hemostasis Overview

**Three components of normal hemostasis**:
1. **Primary hemostasis**: Platelet adhesion, activation, and aggregation (platelet plug)
2. **Secondary hemostasis**: Coagulation cascade activation (fibrin clot)
3. **Fibrinolysis**: Clot breakdown and vessel remodeling

### Coagulation Cascade

**Extrinsic pathway**:
- Tissue factor (TF) + Factor VIIa
- Measured by PT (prothrombin time)

**Intrinsic pathway**:
- Contact activation: Factor XII → XIIa
- Factor XIa → Factor IXa
- Factor IXa + Factor VIIIa (tenase complex)
- Measured by aPTT (activated partial thromboplastin time)

**Common pathway**:
- Factor Xa + Factor Va (prothrombinase complex)
- Prothrombin (Factor II) → Thrombin (Factor IIa)
- Fibrinogen (Factor I) → Fibrin

**Anticoagulant mechanisms**:
- Protein C and Protein S: Inactivate Factors Va and VIIIa
- Antithrombin III: Inactivates thrombin and Factor Xa
- Tissue factor pathway inhibitor (TFPI): Inhibits Factor Xa and TF-VIIa

### Epidemiology

**Hemorrhagic disorders**:
- Hemophilia A: 1 in 5,000 male births
- Hemophilia B: 1 in 25,000 male births
- Von Willebrand disease: 1 in 100-1,000 (most common inherited bleeding disorder)

**Thrombotic disorders**:
- Factor V Leiden: 5% of Caucasians
- Prothrombin G20210A: 2-3% of Caucasians
- Venous thromboembolism: 1-2 per 1,000 person-years
- Disseminated intravascular coagulation (DIC): Complication of severe illness (sepsis, trauma, malignancy)

## Pathophysiology

### Hemophilia A and B

**Hemophilia A**:
- X-linked recessive inheritance
- Deficiency of Factor VIII
- Gene located on Xq28
- Accounts for 80-85% of hemophilia cases

**Hemophilia B** (Christmas disease):
- X-linked recessive inheritance
- Deficiency of Factor IX
- Clinically indistinguishable from hemophilia A

**Severity classification** (based on factor level):
- **Severe**: <1% factor activity
  - Spontaneous bleeding into joints and muscles
- **Moderate**: 1-5% factor activity
  - Bleeding with minor trauma
- **Mild**: 5-40% factor activity
  - Bleeding with significant trauma or surgery

**Pathophysiology**:
- Impaired intrinsic pathway activation
- Inadequate thrombin generation
- Unstable fibrin clot formation
- Prolonged aPTT, normal PT

**Clinical consequences**:
- Hemarthrosis (joint bleeding): Knees, ankles, elbows
- Muscle hematomas
- Intracranial hemorrhage (life-threatening)
- Excessive bleeding with trauma or surgery
- Chronic arthropathy from recurrent hemarthrosis

### Von Willebrand Disease

**Von Willebrand factor (vWF) functions**:
- Mediates platelet adhesion to subendothelial collagen
- Carrier protein for Factor VIII (protects from degradation)

**Types**:

**Type 1** (70-80% of cases):
- Partial quantitative deficiency of vWF
- Autosomal dominant (variable penetrance)
- Proportional decrease in vWF antigen and activity
- Mild bleeding symptoms

**Type 2** (15-20% of cases):
- Qualitative deficiency (dysfunctional vWF)
- Subtypes:
  - **Type 2A**: Decreased platelet adhesion (loss of high molecular weight multimers)
  - **Type 2B**: Increased affinity for platelet GPIb (thrombocytopenia)
  - **Type 2M**: Decreased platelet adhesion (normal multimers)
  - **Type 2N**: Decreased Factor VIII binding (mimics hemophilia A)

**Type 3** (rare):
- Complete absence of vWF
- Autosomal recessive
- Severe bleeding (resembles severe hemophilia)

**Acquired von Willebrand syndrome**:
- Hypothyroidism
- Aortic stenosis (shear stress destroys high molecular weight multimers)
- Lymphoproliferative disorders
- Monoclonal gammopathy

### Disseminated Intravascular Coagulation

**Definition**:
- Systemic activation of coagulation
- Widespread microvascular thrombosis
- Consumption of clotting factors and platelets
- Secondary fibrinolysis

**Triggers**:
- **Sepsis**: Most common cause
- **Trauma**: Massive tissue injury, fat embolism
- **Obstetric complications**: Placental abruption, amniotic fluid embolism, HELLP syndrome
- **Malignancy**: Acute promyelocytic leukemia (M3 AML), mucin-secreting adenocarcinomas
- **Vascular disorders**: Giant hemangioma (Kasabach-Merritt syndrome)
- **Severe hepatic failure**
- **Transfusion reactions**: Hemolytic reactions

**Pathophysiology**:
- Tissue factor release → thrombin generation
- Widespread fibrin deposition in microvasculature
- Consumption of clotting factors (II, V, VIII, fibrinogen) and platelets
- Secondary fibrinolysis → elevated D-dimer, fibrin degradation products
- Microangiopathic hemolytic anemia (MAHA) from RBC fragmentation

**Clinical manifestations**:
- **Bleeding**: Spontaneous, from venipuncture sites, mucosal bleeding
- **Thrombosis**: Organ dysfunction (renal, hepatic, pulmonary), acral ischemia (purpura fulminans)
- **End-organ damage**: Acute kidney injury, ARDS, altered mental status

### Thrombophilia

**Factor V Leiden**:
- Most common inherited thrombophilia
- Mutation in Factor V gene (Arg506Gln)
- Factor V becomes resistant to Protein C inactivation (activated Protein C resistance)
- Autosomal dominant
- Heterozygotes: 5-fold increased VTE risk
- Homozygotes: 50-fold increased VTE risk

**Prothrombin G20210A mutation**:
- Mutation in 3' untranslated region of prothrombin gene
- Elevated prothrombin levels
- 2-3 fold increased VTE risk

**Protein C deficiency**:
- Autosomal dominant
- Protein C inactivates Factors Va and VIIIa
- Deficiency → increased thrombin generation
- Homozygotes: Neonatal purpura fulminans
- Warfarin-induced skin necrosis (rapid fall in Protein C)

**Protein S deficiency**:
- Autosomal dominant
- Protein S is cofactor for Protein C
- Similar thrombotic risk as Protein C deficiency

**Antithrombin III deficiency**:
- Autosomal dominant
- Antithrombin III inhibits thrombin and Factor Xa (enhanced by heparin)
- High thrombotic risk
- Heparin resistance (requires higher doses)

**Antiphospholipid syndrome** (acquired):
- Autoimmune disorder
- Antibodies: Lupus anticoagulant, anticardiolipin, anti-β2-glycoprotein I
- Clinical manifestations:
  - Venous or arterial thrombosis
  - Pregnancy morbidity (recurrent miscarriages)
  - Thrombocytopenia
- Paradoxical prolonged aPTT (lupus anticoagulant interferes with assay)

**Hyperhomocysteinemia**:
- Elevated homocysteine levels
- Causes: MTHFR mutation, B12/folate deficiency, renal failure
- Endothelial damage, prothrombotic state
- Modest thrombotic risk

## Clinical Presentation

### Hemorrhagic Disorders

**History suggestive of bleeding disorder**:
- Easy bruising since childhood
- Prolonged bleeding after minor cuts, dental procedures
- Heavy menstrual bleeding (menorrhagia)
- Postpartum hemorrhage
- Excessive bleeding after surgery or trauma
- Family history of bleeding

**Hemophilia A/B symptoms**:
- **Hemarthrosis**: Spontaneous joint bleeding (knees, ankles, elbows)
  - Acute: Pain, swelling, warmth, decreased range of motion
  - Chronic: Hemophilic arthropathy (joint destruction, deformity)
- **Muscle hematomas**: Spontaneous or post-trauma
  - Iliopsoas hematoma: Hip flexion, groin pain, femoral nerve compression
  - Compartment syndrome: Severe pain, neurovascular compromise
- **Intracranial hemorrhage**: Headache, altered mental status (medical emergency)
- **Mucosal bleeding**: Epistaxis, gingival bleeding, GI bleeding
- **Delayed bleeding**: Bleeding hours to days after trauma (inadequate hemostatic plug)

**Von Willebrand disease symptoms**:
- **Mucocutaneous bleeding**: Predominant feature
  - Epistaxis (nosebleeds): Frequent, prolonged
  - Menorrhagia: Heavy, prolonged menses
  - Gingival bleeding: After dental work
  - Easy bruising
- **Bleeding after dental extractions, surgery**
- **GI bleeding** (less common)
- **Type 3**: Severe bleeding (hemarthrosis, muscle hematomas like hemophilia)

**Distinguishing features**:
- **Hemophilia**: Deep tissue bleeding (joints, muscles), delayed bleeding, males only
- **Von Willebrand disease**: Mucocutaneous bleeding, immediate bleeding, affects both sexes
- **Platelet disorders**: Petechiae, purpura, immediate bleeding

### Disseminated Intravascular Coagulation

**Acute DIC**:
- **Bleeding**: Widespread oozing from venipuncture sites, mucosal bleeding, GI bleeding, hematuria
- **Thrombosis**: Acral cyanosis, digital ischemia, purpura fulminans
- **Organ dysfunction**: Oliguria, hypoxemia, altered mental status
- **Shock**: Hypotension, tachycardia

**Chronic DIC**:
- Compensated state (increased synthesis of clotting factors)
- Thrombotic complications predominate
- Associated with malignancy

### Thrombophilia

**Venous thromboembolism (VTE)**:
- **Deep vein thrombosis (DVT)**: Leg pain, swelling, warmth, Homans sign (unreliable)
- **Pulmonary embolism (PE)**: Dyspnea, chest pain, hemoptysis, tachycardia, hypoxemia

**Arterial thrombosis** (less common):
- Stroke, myocardial infarction (especially antiphospholipid syndrome)

**Unusual sites of thrombosis**:
- Cerebral venous sinus thrombosis: Headache, seizures, focal neurologic deficits
- Mesenteric vein thrombosis: Abdominal pain, bloody diarrhea
- Hepatic vein thrombosis (Budd-Chiari): Hepatomegaly, ascites, abdominal pain
- Portal vein thrombosis

**Triggers for thrombosis**:
- Pregnancy, oral contraceptives, hormone replacement therapy
- Surgery, immobilization, long flights
- Cancer
- Infection, inflammation

**Antiphospholipid syndrome**:
- Recurrent VTE or arterial thrombosis
- Recurrent pregnancy loss (typically >10 weeks gestation)
- Livedo reticularis
- Thrombocytopenia
- Valvular abnormalities (Libman-Sacks endocarditis)

### Physical Examination

**Hemorrhagic disorders**:
- **Skin**: Ecchymoses, petechiae (platelet disorders), purpura
- **Joints**: Swelling, decreased range of motion, chronic deformity (hemophilia)
- **Muscle hematomas**: Palpable masses, tenderness
- **Mucous membranes**: Gingival bleeding, oral petechiae

**DIC**:
- Oozing from venipuncture sites, IV sites, surgical wounds
- Acral cyanosis, digital ischemia
- Purpura fulminans (hemorrhagic skin necrosis)
- Signs of underlying condition (sepsis, shock)

**Thrombophilia**:
- Unilateral leg swelling, calf tenderness (DVT)
- Tachypnea, tachycardia, decreased oxygen saturation (PE)
- Livedo reticularis (antiphospholipid syndrome)

## Diagnosis

### Initial Evaluation

**Screening tests**:
- **PT (prothrombin time)**: Extrinsic and common pathways
  - Normal: 11-13 seconds
  - Prolonged: Factor VII, X, V, II, fibrinogen deficiency; vitamin K deficiency; warfarin
- **aPTT (activated partial thromboplastin time)**: Intrinsic and common pathways
  - Normal: 25-35 seconds
  - Prolonged: Factor VIII, IX, XI, XII deficiency; heparin; lupus anticoagulant
- **Platelet count**: Normal 150,000-400,000/μL
- **Fibrinogen**: Normal 200-400 mg/dL
- **Bleeding time**: Historical, rarely used (platelet function)

**Mixing study**:
- Mix patient plasma 1:1 with normal plasma
- **Corrects**: Factor deficiency (hemophilia)
- **Does not correct**: Inhibitor present (Factor VIII inhibitor, lupus anticoagulant)

### Hemophilia A and B

**Laboratory findings**:
- **Prolonged aPTT**: Isolated finding
- **Normal PT, platelet count, bleeding time**
- **Factor VIII or IX assay**: Reduced activity
  - Hemophilia A: Low Factor VIII
  - Hemophilia B: Low Factor IX
- **Factor VIII/IX inhibitor screen**: Detect neutralizing antibodies (develops in 20-30% of severe hemophilia A)

**Genetic testing**:
- Confirms diagnosis
- Family counseling, carrier detection
- Prenatal diagnosis

**Severity classification**:
- Severe: <1% factor activity
- Moderate: 1-5% factor activity
- Mild: 5-40% factor activity

### Von Willebrand Disease

**Laboratory findings**:
- **Prolonged aPTT**: May be normal in mild cases (Factor VIII reduction)
- **Normal or low Factor VIII**: vWF is carrier protein
- **Low vWF antigen**: Quantitative measure of vWF protein
- **Low vWF activity**: Functional assay (ristocetin cofactor activity or GPIb binding)
- **vWF multimer analysis**: Differentiates subtypes (especially Type 2)
- **Normal platelet count**: Except Type 2B (mild thrombocytopenia)
- **Bleeding time or PFA-100**: May be prolonged (platelet function)

**Type differentiation**:
- **Type 1**: Proportional decrease in vWF antigen and activity
- **Type 2A**: Low activity, decreased high molecular weight multimers
- **Type 2B**: Low activity, absent large multimers, mild thrombocytopenia
- **Type 2M**: Low activity, normal multimers
- **Type 2N**: Normal vWF, low Factor VIII (mimics hemophilia A)
- **Type 3**: Absent vWF antigen and activity

**Confounding factors**:
- Blood type: Type O has 25-30% lower vWF levels (adjust reference range)
- Acute phase reactant: vWF increases with stress, inflammation, pregnancy
- Repeat testing if borderline

### Disseminated Intravascular Coagulation

**Laboratory findings**:
- **Thrombocytopenia**: <150,000/μL (often <50,000/μL)
- **Prolonged PT and aPTT**: Consumption of clotting factors
- **Low fibrinogen**: <200 mg/dL (consumption)
- **Elevated D-dimer**: >500 ng/mL (secondary fibrinolysis)
- **Elevated fibrin degradation products (FDPs)**
- **Schistocytes on blood smear**: Microangiopathic hemolytic anemia (MAHA)
- **Decreased Factor VIII, V, and II**

**Scoring systems**:
- **ISTH DIC score**: Platelet count, D-dimer, PT, fibrinogen
  - Score ≥5: Overt DIC

**Serial testing**:
- Dynamic process, repeat labs to assess progression or response to treatment

### Thrombophilia Workup

**Indications for testing**:
- VTE at age <50 years
- Unprovoked VTE
- Recurrent VTE
- VTE in unusual sites (cerebral, mesenteric, portal veins)
- First-degree relative with VTE at young age
- Pregnancy loss (recurrent, second/third trimester)

**Testing panel**:
- **Factor V Leiden mutation**: PCR-based genetic test
- **Prothrombin G20210A mutation**: PCR-based genetic test
- **Protein C activity**: Functional assay
- **Protein S activity**: Free and total protein S
- **Antithrombin III activity**: Functional assay
- **Lupus anticoagulant**: DRVVT, aPTT-based assay (paradoxically prolongs aPTT)
- **Anticardiolipin antibodies**: IgG, IgM
- **Anti-β2-glycoprotein I antibodies**: IgG, IgM
- **Homocysteine level**

**Timing of testing**:
- **Acute thrombosis**: Genetic tests (Factor V Leiden, prothrombin mutation) can be done anytime
- **After acute thrombosis** (at least 2 weeks off anticoagulation):
  - Protein C, Protein S, antithrombin III (affected by acute thrombosis and anticoagulation)
- **Antiphospholipid antibodies**: Repeat in 12 weeks (must be persistently positive)

**Confounding factors**:
- **Warfarin**: Lowers Protein C and S
- **Heparin**: Lowers antithrombin III
- **Pregnancy, oral contraceptives**: Lower Protein S
- **Acute phase reaction**: Elevates Factor VIII

**Antiphospholipid syndrome criteria** (Revised Sapporo):
- At least 1 clinical criterion:
  - Vascular thrombosis (arterial or venous)
  - Pregnancy morbidity (≥3 unexplained consecutive spontaneous abortions <10 weeks, or ≥1 unexplained fetal death ≥10 weeks, or premature birth <34 weeks due to preeclampsia/placental insufficiency)
- At least 1 laboratory criterion (persistent ≥12 weeks apart):
  - Lupus anticoagulant
  - Anticardiolipin antibody (IgG or IgM, medium/high titer)
  - Anti-β2-glycoprotein I antibody (IgG or IgM)

## Treatment

### Hemophilia A

**Factor VIII replacement**:
- **On-demand therapy**: Treat acute bleeds
  - Minor bleed: 20-30 units/kg (target 40-60% factor level)
  - Major bleed/surgery: 40-50 units/kg (target 80-100% factor level)
  - Half-life: 8-12 hours (repeat dosing every 8-24 hours)
- **Prophylactic therapy**: Prevents bleeding episodes, preserves joint function
  - Severe hemophilia: 25-40 units/kg three times weekly or every other day
  - Target trough level >1% (severe) or 3-5% (moderate)

**Factor VIII products**:
- **Recombinant Factor VIII**: Standard of care (no viral transmission risk)
- **Plasma-derived Factor VIII**: Virus-inactivated
- **Extended half-life products**: PEGylated or Fc fusion proteins (every 3-5 days dosing)

**Desmopressin (DDAVP)**:
- Synthetic vasopressin analog
- Stimulates vWF and Factor VIII release from endothelial cells
- **Indications**: Mild hemophilia A (baseline Factor VIII >5%)
- **Dose**: 0.3 μg/kg IV or 300 μg intranasal
- **Effect**: 2-4 fold increase in Factor VIII (temporary, 6-8 hours)
- **Side effects**: Hyponatremia, water retention, tachyphylaxis
- **Contraindications**: Severe hemophilia, cardiovascular disease

**Antifibrinolytics**:
- **Tranexamic acid**: 1300 mg TID or 25 mg/kg TID
- **Aminocaproic acid**: 5 g loading, then 1-1.25 g hourly
- Stabilize clot, prevent fibrinolysis
- Adjunct for oral bleeding, dental procedures, epistaxis
- **Avoid in hematuria** (risk of ureteral obstruction from clot)

**Management of inhibitors** (neutralizing antibodies to Factor VIII):
- **Immune tolerance induction**: High-dose Factor VIII (50-200 units/kg daily) for months to years
- **Bypassing agents**: For acute bleeds in patients with inhibitors
  - Recombinant Factor VIIa (NovoSeven): 90 μg/kg every 2-3 hours
  - Activated prothrombin complex concentrate (aPCC, FEIBA): 50-100 units/kg every 8-12 hours
- **Emicizumab**: Bispecific antibody (bridges Factor IXa and X, mimics Factor VIIIa)
  - Prophylaxis in hemophilia A with or without inhibitors
  - Subcutaneous weekly dosing

**Gene therapy**:
- Investigational
- AAV vector-mediated Factor VIII gene delivery
- Promising results in clinical trials

### Hemophilia B

**Factor IX replacement**:
- **On-demand therapy**: Treat acute bleeds
  - Minor bleed: 30-40 units/kg (target 40-60% factor level)
  - Major bleed/surgery: 80-100 units/kg (target 80-100% factor level)
  - Half-life: 18-24 hours (longer than Factor VIII)
- **Prophylactic therapy**: 40-60 units/kg twice weekly

**Factor IX products**:
- **Recombinant Factor IX**: Standard of care
- **Plasma-derived Factor IX**: Virus-inactivated
- **Extended half-life products**: Fc fusion, PEGylated (weekly dosing)

**Management of inhibitors**:
- Less common than hemophilia A (3-5%)
- Bypassing agents (Factor VIIa, aPCC)
- Immune tolerance induction

**Gene therapy**:
- AAV vector-mediated Factor IX gene delivery
- FDA-approved: Hemgenix (etranacogene dezaparvovec)

### Von Willebrand Disease

**Desmopressin (DDAVP)**:
- **First-line for Type 1 and Type 2A**
- Increases vWF and Factor VIII release
- **Dose**: 0.3 μg/kg IV or 300 μg intranasal
- **Contraindicated in Type 2B**: Worsens thrombocytopenia (enhances platelet binding)
- **Test response**: Trial before elective procedure (measure vWF and Factor VIII at 1 and 4 hours)

**vWF/Factor VIII concentrate**:
- **Indications**:
  - Severe bleeding or major surgery
  - Type 3 vWD
  - Type 2B vWD (avoid DDAVP)
  - Inadequate response to DDAVP
- **Products**: Humate-P, Alphanate, Wilate (contain both vWF and Factor VIII)
- **Dose**: 40-60 units/kg for major bleeding or surgery

**Antifibrinolytics**:
- Tranexamic acid or aminocaproic acid
- Adjunct for mucosal bleeding, dental procedures, menorrhagia

**Hormonal therapy**:
- **Oral contraceptives**: Reduce menorrhagia
- Increase vWF levels

**Topical agents**:
- Thrombin, fibrin sealants for local hemostasis

### Disseminated Intravascular Coagulation

**Treat underlying cause** (most important):
- Antibiotics for sepsis
- Delivery of fetus (obstetric complications)
- Chemotherapy (acute promyelocytic leukemia)

**Supportive care**:
- **Platelet transfusion**: If platelets <50,000/μL and bleeding or <10,000-20,000/μL (prophylactic)
- **Fresh frozen plasma (FFP)**: Replenish clotting factors (10-15 mL/kg)
- **Cryoprecipitate**: If fibrinogen <100 mg/dL (10 units raises fibrinogen ~70 mg/dL)
- **Packed red blood cells**: Maintain hemoglobin >7 g/dL

**Anticoagulation** (controversial):
- **Low-dose heparin**: May be considered in thrombotic DIC (not bleeding DIC)
- Unfractionated heparin 5-10 units/kg/hour without bolus
- Limited evidence, use cautiously

**Antifibrinolytics**:
- **Generally avoided** (risk of thrombosis)
- Exception: DIC with hyperfibrinolysis (e.g., acute promyelocytic leukemia with ATRA therapy)

**Monitor response**:
- Serial PT, aPTT, fibrinogen, platelet count, D-dimer
- Normalize as underlying condition resolves

### Thrombophilia

**Acute VTE treatment**:
- **Anticoagulation**: See pulmonary embolism section
- Initial: LMWH, fondaparinux, or DOACs
- Long-term: Warfarin (INR 2-3) or DOACs

**Duration of anticoagulation**:
- **Provoked VTE** (surgery, trauma, immobilization): 3 months
- **Unprovoked VTE**: At least 3 months, consider indefinite if low bleeding risk
- **Recurrent VTE**: Indefinite anticoagulation
- **Thrombophilia**: Variable, often indefinite for high-risk thrombophilia (homozygous Factor V Leiden, antiphospholipid syndrome)

**Specific thrombophilias**:
- **Factor V Leiden, prothrombin mutation** (heterozygous): 3-6 months after first provoked VTE, consider longer if unprovoked
- **Protein C/S/antithrombin III deficiency**: Indefinite anticoagulation after first VTE
- **Antiphospholipid syndrome**: Indefinite anticoagulation (high recurrence risk)
  - **Arterial thrombosis**: Warfarin INR 2-3 (DOACs less effective)
  - **Recurrent VTE on anticoagulation**: Consider higher INR target (2.5-3.5)

**Pregnancy management**:
- **History of VTE + thrombophilia**: Prophylactic LMWH throughout pregnancy, 6 weeks postpartum
- **No history of VTE + high-risk thrombophilia**: Consider prophylactic LMWH
- Warfarin and DOACs contraindicated in pregnancy

**Antiphospholipid syndrome in pregnancy**:
- **Aspirin 81 mg daily** + **prophylactic LMWH**
- Reduces pregnancy loss from 90% to 20-30%

**Thromboprophylaxis**:
- High-risk situations: Surgery, hospitalization, prolonged immobilization
- LMWH, fondaparinux, or DOACs

**Avoid thrombotic triggers**:
- Estrogen-containing oral contraceptives (consider progestin-only or non-hormonal)
- Hormone replacement therapy
- Smoking cessation

## Complications

### Hemophilia

- **Hemophilic arthropathy**: Chronic joint damage from recurrent hemarthrosis
  - Joint deformity, ankylosis, chronic pain
  - Preventable with prophylactic factor replacement
- **Pseudotumor**: Encapsulated hematoma in bone or soft tissue (mimics tumor)
- **Intracranial hemorrhage**: Leading cause of death (10-20% mortality)
- **Inhibitor development**: 20-30% of severe hemophilia A, 3-5% of hemophilia B
- **Transfusion-transmitted infections**: HIV, hepatitis C (historical, rare with modern products)

### Von Willebrand Disease

- **Bleeding complications**: Postoperative, dental procedures, menorrhagia
- **Iron deficiency anemia**: Chronic blood loss

### Disseminated Intravascular Coagulation

- **Multiorgan failure**: Kidney, liver, lung, brain dysfunction
- **Severe bleeding**: Intracranial hemorrhage, GI bleeding
- **Mortality**: 30-50% depending on underlying cause and severity

### Thrombophilia

- **Recurrent VTE**: 5-10% annual recurrence risk off anticoagulation
- **Post-thrombotic syndrome**: Chronic leg pain, swelling, venous insufficiency (30% after DVT)
- **Chronic thromboembolic pulmonary hypertension**: Rare after PE
- **Anticoagulation complications**: Major bleeding 1-3% per year on warfarin/DOACs
- **Pregnancy complications**: Thrombosis risk increased 5-10 fold during pregnancy and postpartum

**Antiphospholipid syndrome-specific**:
- **Catastrophic antiphospholipid syndrome**: Multi-organ thrombosis (rare, high mortality)
- **Recurrent pregnancy loss**: 90% without treatment

## Prognosis

### Hemophilia

**With treatment**:
- **Near-normal lifespan**: With prophylactic factor replacement and modern therapies
- **Quality of life**: Improved with prophylaxis (prevents arthropathy)

**Without treatment**:
- **Historical mortality**: High mortality in childhood
- **Severe disability**: Chronic arthropathy

**Factors affecting prognosis**:
- Severity of hemophilia
- Access to factor replacement therapy
- Development of inhibitors (worse prognosis)
- Adherence to prophylaxis

### Von Willebrand Disease

- **Excellent prognosis**: Mild bleeding disorder, rarely life-threatening
- **Type 3**: More severe, requires regular monitoring and treatment

### Disseminated Intravascular Coagulation

- **Mortality**: 30-50% overall
  - Depends on underlying cause and severity
  - Sepsis-associated DIC: 40-50% mortality
  - Trauma-associated DIC: 20-30% mortality
- **Survivors**: Risk of organ dysfunction (renal failure, pulmonary fibrosis)

### Thrombophilia

- **Recurrence risk**: Variable depending on thrombophilia type
  - Factor V Leiden heterozygote: Low recurrence risk if provoked VTE
  - Antiphospholipid syndrome: High recurrence risk (30-50% over 5 years without anticoagulation)
- **Quality of life**: Impacted by chronic anticoagulation, post-thrombotic syndrome
- **Mortality**: Increased with recurrent VTE, PE

## Key Points

- Hemophilia A (Factor VIII deficiency) and B (Factor IX deficiency) are X-linked bleeding disorders; severity correlates with factor level (<1% severe, 1-5% moderate, 5-40% mild)
- Hemophilia presents with deep tissue bleeding (hemarthrosis, muscle hematomas) and prolonged aPTT; treatment is factor replacement (on-demand or prophylactic)
- Von Willebrand disease is the most common inherited bleeding disorder; Type 1 (70-80%) has partial quantitative deficiency; desmopressin is first-line for Type 1
- DIC is consumptive coagulopathy triggered by sepsis, trauma, obstetric complications, or malignancy; treat underlying cause and provide supportive transfusion therapy
- Factor V Leiden is the most common inherited thrombophilia (5% of Caucasians); heterozygotes have 5-fold increased VTE risk
- Antiphospholipid syndrome causes venous/arterial thrombosis and pregnancy morbidity; requires persistent positive antibodies (lupus anticoagulant, anticardiolipin, anti-β2-GPI)
- Thrombophilia workup includes Factor V Leiden, prothrombin G20210A, Protein C/S, antithrombin III, antiphospholipid antibodies; test after acute thrombosis resolves
- Anticoagulation duration for VTE: 3 months (provoked), indefinite (unprovoked, high-risk thrombophilia, recurrent VTE)

## References

1. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1-158.

2. Leebeek FWG, Eikenboom JCJ. Von Willebrand's Disease. N Engl J Med. 2016;375(21):2067-2080.

3. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the Diagnosis and Management of Disseminated Intravascular Coagulation. Br J Haematol. 2009;145(1):24-33.

4. Bauer KA. Factor V Leiden. UpToDate. 2023.

5. Miyakis S, Lockshin MD, Atsumi T, et al. International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.

6. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352.

7. Franchini M, Mannucci PM. Inhibitors of Propagation of Coagulation (Factors VIII, IX and XI): A Review of Current Therapeutic Practice. Br J Clin Pharmacol. 2011;72(4):553-562.

8. Schramm W. The History of Haemophilia – A Short Review. Thromb Res. 2014;134(Suppl 1):S4-S9.

9. Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of Direct Oral Anticoagulants in Women of Childbearing Potential: Guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(8):1673-1676.

10. Lipe B, Ornstein DL. Deficiencies of Natural Anticoagulants, Protein C, Protein S, and Antithrombin. Circulation. 2011;124(14):e365-e368.
